208 related articles for article (PubMed ID: 24244671)
1. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.
Huang D; Lu N; Fan Q; Sheng W; Bu H; Jin X; Li G; Liu Y; Li X; Sun W; Zhang H; Li X; Zhou Z; Yan M; Wang X; Sha W; Ji J; Cheng X; Zhou Z; Xu J; Du X
PLoS One; 2013; 8(11):e80290. PubMed ID: 24244671
[TBL] [Abstract][Full Text] [Related]
2. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
4. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
5. HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study.
Kim WH; Gomez-Izquierdo L; Vilardell F; Chu KM; Soucy G; Dos Santos LV; Monges G; Viale G; Brito MJ; Osborne S; Noé J; Du X
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):239-245. PubMed ID: 27490762
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.
Baykara M; Benekli M; Ekinci O; Irkkan SC; Karaca H; Demirci U; Akinci MB; Unal OU; Dane F; Turkoz FP; Balakan O; Eser EP; Ozturk SC; Ozkan M; Oksuzoglu B; Sevinc A; Demir N; Harputluoglu H; Yalcin B; Coskun U; Uner A; Ozet A; Buyukberber S;
J Gastrointest Surg; 2015 Sep; 19(9):1565-71. PubMed ID: 26179664
[TBL] [Abstract][Full Text] [Related]
7. [Dual-color silver-enhanced in-situ hybridization for determination of HER2 gene amplification in gastric carcinoma].
Fan D; Li Y; Ran W; Yu W; Li H
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):4-7. PubMed ID: 24713241
[TBL] [Abstract][Full Text] [Related]
8. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
9. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
[TBL] [Abstract][Full Text] [Related]
10. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
11. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.
Jeung J; Patel R; Vila L; Wakefield D; Liu C
Arch Pathol Lab Med; 2012 Jun; 136(6):610-7. PubMed ID: 22646266
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
14. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
[TBL] [Abstract][Full Text] [Related]
15. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.
Sheng WQ; Huang D; Ying JM; Lu N; Wu HM; Liu YH; Liu JP; Bu H; Zhou XY; Du X
Ann Oncol; 2013 Sep; 24(9):2360-4. PubMed ID: 23788757
[TBL] [Abstract][Full Text] [Related]
16. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
20. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
